GNI Group Ltd
TSE:2160
Intrinsic Value
GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. [ Read More ]
The intrinsic value of one GNI Group Ltd stock under the Base Case scenario is 4 558.29 JPY. Compared to the current market price of 2 446 JPY, GNI Group Ltd is Undervalued by 46%.
Valuation Backtest
GNI Group Ltd
Run backtest to discover the historical profit from buying and selling GNI Group Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
GNI Group Ltd
Current Assets | 30.9B |
Cash & Short-Term Investments | 23.2B |
Receivables | 4B |
Other Current Assets | 3.7B |
Non-Current Assets | 31.5B |
Long-Term Investments | 4.2B |
PP&E | 6.1B |
Intangibles | 21B |
Other Non-Current Assets | 328.3m |
Current Liabilities | 8.2B |
Accounts Payable | 2.1B |
Short-Term Debt | 1.3B |
Other Current Liabilities | 4.8B |
Non-Current Liabilities | 20.4B |
Long-Term Debt | 1.8B |
Other Non-Current Liabilities | 18.7B |
Earnings Waterfall
GNI Group Ltd
Revenue
|
26B
JPY
|
Cost of Revenue
|
-3.6B
JPY
|
Gross Profit
|
22.4B
JPY
|
Operating Expenses
|
-17.3B
JPY
|
Operating Income
|
5.2B
JPY
|
Other Expenses
|
2.9B
JPY
|
Net Income
|
8.1B
JPY
|
Free Cash Flow Analysis
GNI Group Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
GNI Group Ltd's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
Score
GNI Group Ltd's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
GNI Group Ltd's solvency score is 90/100. The higher the solvency score, the more solvent the company is.
Score
GNI Group Ltd's solvency score is 90/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
GNI Group Ltd
According to Wall Street analysts, the average 1-year price target for GNI Group Ltd is 4 182 JPY with a low forecast of 4 141 JPY and a high forecast of 4 305 JPY.
Shareholder Return
Price
GNI Group Ltd
Average Annual Return | 24.19% |
Standard Deviation of Annual Returns | 90.21% |
Max Drawdown | -75% |
Market Capitalization | 121.9B JPY |
Shares Outstanding | 49 860 200 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 629 full-time employees. The company went IPO on 2007-08-31. The firm is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. The company is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).
Contact
IPO
Employees
Officers
The intrinsic value of one GNI Group Ltd stock under the Base Case scenario is 4 558.29 JPY.
Compared to the current market price of 2 446 JPY, GNI Group Ltd is Undervalued by 46%.